Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business board appointment

Alkermes Appoints Anne Whitaker to Board

Analysis based on 7 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
2
Attention
0
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The appointment of an independent director to Alkermes' board is a routine governance matter with minimal immediate impact on the company's stock, which traded nearly flat at 46.01 dollars on the Nasdaq. The addition of a seasoned biopharmaceutical executive with commercial and operational expertise may modestly support investor confidence in the company's strategic execution over the longer term.

biopharmaceutical pharmaceutical

Alkermes (Nasdaq: ALKS) announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. The appointment was announced on Wednesday, September 16, 2026, according to a company press release. Whitaker is a seasoned biopharmaceutical executive and experienced board director with deep commercial and operational expertise and a proven track record of driving growth and transformation across global pharmaceutical and biotechnology organizations. She most recently served as chief executive officer of Ajax Therapeutics, a then clinical-stage biopharmaceutical company. Prior to Aerami, she served as CEO of Novoclem Therapeutics, Inc. and Synta Pharmaceuticals Corporation. Earlier in her career she held senior commercial and executive leadership positions at Bausch Health, Inc., Sanofi S.A. and GlaxoSmithKline. Whitaker currently serves on the boards of publicly traded companies Basilea Pharmaceutica Ltd and ICON PLC, and on the boards of private companies QurAlis LLC, Bespak, Inc., Beaconcure Technologies and Trinity Partners, LLC. She previously served on the boards of Nykode Therapeutics, OraSure Technologies, Inc., Ergomed plc and Faron Pharmaceuticals. She holds a B.S. in chemistry with a minor in business administration from the University of North Alabama. Alkermes CEO Blair Jackson said Anne joins the Board at a defining time for the company, citing strong commercial performance and a differentiated pipeline in neuroscience. Chairman Richard Pops also welcomed her, noting her experience as an executive and CEO across organizations of varying sizes and stages. Alkermes is headquartered in the Republic of Ireland with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. On the Nasdaq, Alkermes shares were trading 0.03 percent down at 46.01 dollars following the announcement.

90 Alkermes appointed independent director Mike Whitaker
stock
Alkermes is the company making the board appointment; the addition of Mike Whitaker strengthens its board with biopharmaceutical commercial and operational expertise. The market reaction was muted, with shares trading nearly flat.
Importance 100.0 Sentiment 2.0
per
Whitaker is the newly appointed independent director, bringing CEO and board experience across multiple pharmaceutical and biotechnology companies to Alkermes.
Importance 95.0 Sentiment 5.0
per
Jackson, Alkermes President and CEO, commented on the appointment, framing it as valuable to the company's strategy and pipeline execution.
Importance 30.0 Sentiment 0.0
per
Pops, Chairman of the Alkermes Board, welcomed Whitaker and highlighted her executive and board experience.
Importance 25.0 Sentiment 0.0
exch
Nasdaq is the exchange where Alkermes shares trade; the stock was quoted at 46.01 dollars, down 0.03 percent.
Importance 10.0 Sentiment 0.0
priv
Aerami is Whitaker's most recent CEO role, cited as part of her background; no direct impact from the event.
Importance 10.0 Sentiment 0.0
cnt
The United States hosts Alkermes' corporate office, R&D center in Massachusetts and manufacturing facility in Ohio, mentioned as background.
Importance 5.0 Sentiment 0.0
cnt
Ireland is the headquarters location of Alkermes, mentioned as background.
Importance 5.0 Sentiment 0.0
priv
Novoclem is a former CEO role of Whitaker, mentioned only as background.
Importance 5.0 Sentiment 0.0
priv
Synta is a former CEO role of Whitaker, mentioned only as background.
Importance 5.0 Sentiment 0.0
stock
Bausch Health is a former employer of Whitaker, mentioned only as background.
Importance 5.0 Sentiment 0.0
stock
Sanofi is a former employer of Whitaker, mentioned only as background.
Importance 5.0 Sentiment 0.0
stock
GSK is a former employer of Whitaker, mentioned only as background.
Importance 5.0 Sentiment 0.0
stock
Basilea is a company where Whitaker currently serves on the board, mentioned as background.
Importance 5.0 Sentiment 0.0
stock
ICON is a company where Whitaker currently serves on the board, mentioned as background.
Importance 5.0 Sentiment 0.0
+ 9 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.